280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial.
Saved in:
| Title: | 280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial. |
|---|---|
| Authors: | Eto, M.1 (AUTHOR), Motzer, R.J.2 (AUTHOR), Choueiri, T.K.3 (AUTHOR), Haanen, J.B.A.G.4 (AUTHOR), Oya, M.5 (AUTHOR), Uemura, H.6 (AUTHOR), Venugopal, B.7 (AUTHOR), Rini, B.I.8 (AUTHOR), Miyake, H.9 (AUTHOR), Albiges, L.10 (AUTHOR), Schmidinger, M.11 (AUTHOR), Tomita, Y.12 (AUTHOR), Umeyama, Y.13 (AUTHOR), Ellers-Lenz, B.14 (AUTHOR), Hoffman, J.15 (AUTHOR), Larkin, J.16 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 4, Vol. 35, pS1512-S1513. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
